Navigation Links
Linking EudraCT and ClinicalTrials.gov Records Provides Huge Benefit
Date:11/15/2011

LONDON, November 15, 2011 /PRNewswire/ --

EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply consensus forecasts of global drug sales, announced today the launch of its new clinical trial intelligence service, EP Clinical Trials[SM]. By linking EudraCT and ClinicalTrials.gov records, the new service delivers a unique synthesis of clinical trials information that will greatly benefit companies as they manage clinical trial strategies, plan clinical development programs, or seek out investment opportunities.

"Currently 52% (15,900+ trial records) of the EudraCT clinical trial data, originally released in March 2011, has been made public, and we have successfully linked half of this data via NCT-ID reference number to ClinicalTrials.gov records," said Anthony Raeside, Head of Research at EvaluatePharma®,"Our goal is to continue to make the data as meaningful and valuable as possible by indexing, linking, and revealing previously un-recognised synergies between the public clinical trial directories."

By linking the two leading sources of clinical trial records, a few examples of additional information benefit includes:

  • Enrolment numbers available for each EU country
  • Trials identified for orphan (rare disease) indications
  • Standardized technology for investigational drugs disclosed, such as biologic - gene therapy
  • Standardized pharmaceutical form such as transdermal patch
  • Ability to identify commercial company trials unique to the EudraCT site

EP Clinical Trials[SM] updated daily, also provides mapped data such as biopharmaceutical company and product information, peak and historical sales, indication, top level deal information, custom data alerts and award winning EP Vantage® commentary and analysis.

About EvaluatePharma Ltd

The research company EvaluatePharma Ltd was the first to supply consensus forecasts of global drug sales and now provides standardized worldwide financial and forecast models with consensus product sales forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A activity. Launched in 2007, EvaluatePharma®Alpha offers a Net Present Value (NPV) valuation service quantifying market events and the impact on product, portfolio and company valuation including the daily online news service EP Vantage®.

EvaluatePharma®, EvaluatePharma®Alpha, and EP Vantage® are services of EvaluatePharma Ltd, headquartered in London, England. In North America, EvaluatePharma Ltd is represented by EvaluatePharma USA, Inc.

http://www.evaluatepharma.com

Media Contacts:

Andrew Beaven
Marketing Director, EvaluatePharma Ltd
T: +44(0)20-7539-1818
E: andrewb@evaluatepharma.com
EvaluatePharma Ltd
11-29 Fashion Street
London
E1 6PX
United Kingdom

Christine Lindgren
EvaluatePharma USA, Inc
T: +1-617-573-9458
E: christinel@evaluatepharma.com
EvaluatePharma Ltd
15 Broad St.
Suite 401
Boston, MA
02109


'/>"/>
SOURCE EvaluatePharma Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
2. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
3. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
4. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
5. Clinical Care Options Announces Addition of ClinicalTrials.gov Database to CCO inPractice™ Point-of-Care Resource
6. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
7. Aprima and MednetwoRx Partner to Provide Electronic Health Records and Remote Hosting Option to Physician Practices
8. Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation
9. Novalung Records 50% Growth
10. Huntington Financing Package Supports Major Regional Medical Center Electronic Medical Records Project
11. Elekta Impac Software to Demonstrate Oncology EHR Capabilities at Electronic Health Records Lab in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
Breaking Medicine News(10 mins):